Related Experiment Video

Updated: Mar 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells

Alicia M Waters1, Laura L Stafman1, Evan F Garner1

  • 1Department of Surgery, Division of Pediatric Surgery, University of Alabama, Birmingham, AL.

Translational Oncology
|August 29, 2016
PubMed

Insights

Focal adhesion kinase (FAK) inhibition significantly reduced rhabdomyosarcoma (RMS) growth, invasion, and migration while increasing apoptosis. This study highlights FAK as a potential therapeutic target for challenging pediatric RMS tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Rhabdomyosarcoma (RMS) remains a significant therapeutic challenge in pediatric oncology, particularly for metastatic or relapsed cases.
  • Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase, plays a crucial role in various aspects of tumorigenesis, including sarcoma development.

Purpose of the Study:

  • To investigate the presence and role of FAK in pediatric RMS.
  • To evaluate the therapeutic potential of FAK inhibition in RMS.

Main Methods:

  • Analysis of FAK expression and phosphorylation in RMS tumor specimens and cell lines.
  • Inhibition of FAK using RNA interference (RNAi) and small molecule inhibitors in RMS cell lines.
  • Assessment of cellular survival, invasion, migration, and apoptosis following FAK inhibition.
  • Evaluation of FAK inhibition on RMS tumor growth in a xenograft mouse model.

Main Results:

  • FAK was found to be present and phosphorylated in pediatric RMS tumor samples and cell lines.
  • FAK inhibition led to reduced cellular survival, invasion, and migration.
  • FAK inhibition significantly increased apoptosis in RMS cells.
  • Small molecule inhibition of FAK suppressed tumor growth in an RMS xenograft model.

Conclusions:

  • FAK is present and active in RMS, contributing to tumor progression.
  • Targeting FAK demonstrates therapeutic promise for treating pediatric RMS.
  • FAK inhibition offers a potential novel strategy for difficult-to-treat RMS.

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K